Levetiracetam Injection
Product Images NDC 43598-759

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43598-759). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000carton.jpg (1000carton)

Packaging label for Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL) intravenous infusion. The label indicates 10 single-dose bags and is branded as Novaplus. Manufactured by Gland Pharma Limited, Hyderabad, India, with Dr.Reddy's Laboratories Inc as the labeler. Includes NDC 43598-757-10.*

FDA Label Image

1500 Carton.jpg (1500carton)

Packaging label for Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) intravenous infusion. The label indicates 10 single-dose bags per package, manufactured by Dr.Reddy's Laboratories Inc under the Novaplus brand. Label includes dosing, storage, and usage instructions.*

FDA Label Image

500carton.jpg (500caton)

Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL (5 mg/mL) intravenous infusion, packaged as 10 single-dose bags. The label shows directions for intravenous infusion use, manufacturer details (Gland Pharma Limited), and the labeler as Dr.Reddy's Laboratories Inc. The brand name 'novaplus' appears on the packaging.*

FDA Label Image

Figure1 (Figure1)

A bar graph depicting the percentage of patients for placebo and two dosages of Levetiracetam Injection (1000 mg/day and 3000 mg/day). The graph shows patient response rates at 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day, with statistical significance indicated for the Levetiracetam groups versus placebo.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The chart notes statistically significant differences versus placebo for both Levetiracetam doses.*

FDA Label Image

Figure3 (Figure3)

A bar chart comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day treatment. The graph shows approximately 14.4% of patients in the placebo group and 39.4% in the Levetiracetam group, with a notation indicating statistical significance versus placebo.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=84) shows 45.2% of patients, while the Levetiracetam group (N=79) shows 72.2%, marked as statistically significant versus placebo.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Levetiracetam showing its molecular components and bonding arrangement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.